Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions
Genetic Basis of Neuroblastoma Tumorigenesis
4 other identifiers
observational
9,350
1 country
2
Brief Summary
This laboratory study is looking at genes in participants with neuroblastoma or noncancerous conditions. Identifying genes related to cancer may help in the study of cancer. It may also help doctors predict who is at risk of developing neuroblastoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 11, 2006
CompletedFirst Submitted
Initial submission to the registry
February 15, 2007
CompletedFirst Posted
Study publicly available on registry
February 19, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 5, 2016
CompletedAugust 7, 2018
October 1, 2017
9.4 years
February 15, 2007
August 3, 2018
Conditions
Outcome Measures
Primary Outcomes (5)
Neuroblastoma predisposition genes
Up to 4 years
Single nucleotide polymorphism (SNP) allele disease association
Up to 4 years
SNP haplotype disease association
Up to 4 years
Validation of SNP allele and haplotype disease association
Up to 4 years
SNP association with phenotypic subsets (i.e., high-risk vs no high-risk disease; MYCN amplification vs no MYCN amplification)
Up to 4 years
Study Arms (1)
Ancillary-correlative (SNP analysis)
DNA samples are derived from participants' banked blood or uninvolved bone marrow. A whole genome scan of DNA samples is employed to identify candidate single nucleotide polymorphisms (SNPs). The candidate SNPs are investigated, using a gene-centric haplotyping approach, to identify 10-20 true disease-associated alleles. The disease-associated alleles are again investigated, using a gene-centric haplotyping approach, to validate 5-10 disease-associated SNPs. SNPs are then analyzed for heritable predisposition.
Interventions
Eligibility Criteria
You may qualify if:
- Patient:
- Diagnosis of neuroblastoma
- Banked constitutional and genomic DNA within COG-ANBL00B1 Neuroblastoma Biology protocol or another COG Biology Protocol
- At least 1.0 ?g of DNA available
- Control (age, race, and gender-matched):
- No diagnosis of cancer
- May have other conditions, including any of the following:
- Asthma
- Inflammatory bowel disease
- Attention-deficit disorder
- Obesity
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Children's Oncology Grouplead
- National Cancer Institute (NCI)collaborator
Study Sites (2)
University of Mississippi Medical Center
Jackson, Mississippi, 39216, United States
Childrens Oncology Group
Philadelphia, Pennsylvania, 19104, United States
Biospecimen
Blood, Bone Marrow
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
John Maris
Children's Oncology Group
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 15, 2007
First Posted
February 19, 2007
Study Start
December 11, 2006
Primary Completion
May 5, 2016
Last Updated
August 7, 2018
Record last verified: 2017-10